UCL ranked among Europe’s leading universities for spinouts in Royal Academy of Engineering report

The role of UCL Business (UCL Ventures), UCL’s expert commercialisation partner, is highlighted in helping researchers translate breakthrough discoveries into companies that attract investment and deliver real-world impact.

Recognising UCL’s strength in turning world-leading research into high-growth businesses with global potential, the report provides a data-driven picture of the UK university spinout ecosystem since 2010. It examines how effectively research is translated into high-growth companies across spinout creation, funding, sectors, exits and equity structures in the UK and Europe.

The UK leads Europe in spinout value creation, according to the report, with more than 2,000 spinouts worth around £49bn created in the last 16 years. It shows that new ventures stemming from universities are overwhelmingly focused on deep tech, accounting for 96% of value, with the life sciences, AI and quantum sectors dominating within this category. Progression to later funding stages, meanwhile, is at least as strong as, and in some cases stronger than, the wider tech sector.

Against this backdrop, the report showcases that UCL spinouts have raised close to £2bn in funding, created around £5.5bn in value, and produced 64 venture capital-backed companies. This reinforces UCL’s position as one of the UK’s leading centres for deep tech commercialisation, and UCL Ventures’s role – to combine world-class research with structured, expert support that helps translate ideas into credible, investable businesses.

The Golden Triangle of innovation

As part of the London cluster within the ‘Golden Triangle’ of Oxford, Cambridge and London, UCL continues to play a major role in one of Europe’s most successful innovation ecosystems. The findings also reinforce UCL’s strength in life sciences and health-related deep tech, where exit performance stands out: UCL accounts for seven of the UK’s top 20 spinout exits in the past decade, second only to the University of Oxford.

Dr. Anne Lane, CEO of UCL Business, said: “UCL’s performance in this year’s Spotlight on Spinouts report is a powerful reflection of the university’s ability to turn world-leading research into ventures with global potential. It also highlights the importance of strong commercialisation support. At UCL Ventures, we work closely with founders to protect and develop their ideas, build investable businesses and help ensure that breakthrough science and innovation can achieve meaningful impact in the world.”

UCL Ventures’s role supporting spinouts

One of UCL Ventures’s top exits by value mentioned in the report is Autolus Therapeutics: a UCL spinout which has pioneered a leap forward from conventional immunotherapy to treat acute lymphoblastic leukaemia (ALL). This so-called ‘living medicine’ utilises a patients’ own immune cells, reprogrammed with the unique signature of their cancer, so they can target and destroy cancer cells and then retain that ability to prevent recurrence.

Supported at an early stage through Proof of Concept funding, the company has gone on to raise more than $1.1bn in investment since incorporation, employing more than 450 people and opening a state-of-the-art global manufacturing facility in Hertforshire. UCL Ventures supported the business from the outset by helping to establish the spinout, managing intellectual property and building partnerships.

Across life sciences, deep tech, med tech, AI, quantum, photonics and advanced materials, UCL Ventures spinouts are tackling major global challenges while generating economic value and delivering benefits for patients, communities and industry.

The Royal Academy of Engineering’s findings underline the importance of strong commercialisation support in translating research excellence into real-world outcomes — a role UCL Ventures continues to play across UCL’s innovation pipeline.

Read the full report here.